Drug Trial Radar · NCT05279417
ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
251
Actual
Start
Feb 1, 2022
Primary completion
Sep 5, 2023
Study completion Oct 11, 2023
Sponsor
- Lead sponsor
- Aclaris Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates ATI-450 plus MTX versus placebo plus MTX in participants with moderate to severe active RA who have had an inadequate response to MTX alone.
Conditions
- Rheumatoid Arthritis
Interventions
ATI-450 50 mg oral tablet BIDDrug
Oral, small molecule MK2 inhibitor
Placebo oral tabletDrug
Placebo tablet manufactured to match ATI-450 in appearance
MethotrexateDrug
15 mg to 25 mg weekly
ATI-450 20 mg oral tablet BIDDrug
Oral, small molecule MK2 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving ACR20 at Week 12Time frame: Week 12
Locations
50 sites in 4 countries. Site status is shown where the registry gives one.
Aclaris Investigational Site
El Cajon, California
Aclaris Investigational Site
Encino, California
Aclaris Investigational Site
La Jolla, California
Aclaris Investigational Site
Palm Desert, California
Aclaris Investigational Site
Tampa, Florida
Aclaris Investigational Site
Oklahoma City, Oklahoma
Aclaris Investigational Site
Duncansville, Pennsylvania
Aclaris Investigational Site
Jackson, Tennessee
Aclaris Investigational Site
Cypress, Texas
Aclaris Investigational Site
Mesquite, Texas
Aclaris Investigational Site
San Antonio, Texas
Aclaris Investigational Site
Pleven, Bulgaria
Aclaris Investigational Site
Plovdiv, Bulgaria
Aclaris Investigational Site
Plovdiv, Bulgaria
Aclaris Investigational Site
Plovdiv, Bulgaria
Aclaris Investigational Site
Plovdiv, Bulgaria
Aclaris Investigational Site
Sofia, Bulgaria
Aclaris Investigational Site
Sofia, Bulgaria
Aclaris Investigational Site
Sofia, Bulgaria
Aclaris Investigational Site
Varna, Bulgaria
Aclaris Investigational Site
Brno, Czechia
Aclaris Investigational Site
Hlučín, Czechia
Aclaris Investigational Site
Ostrava, Czechia
Aclaris Investigational Site
Pardubice, Czechia
Aclaris Investigational Site
Prague, Czechia
Aclaris Investigational Site
Prague, Czechia
Aclaris Investigational Site
Uherské Hradiště, Czechia
Aclaris Investigational Site
Bialystok, Poland
Aclaris Investigational Site
Bialystok, Poland
Aclaris Investigational Site
Dąbrówka, Poland
Aclaris Investigational Site
Krakow, Poland
Aclaris Investigational Site
Lublin, Poland
Aclaris Investigational Site
Nowa Sól, Poland
Aclaris Investigational Site
Poznan, Poland
Aclaris Investigational Site
Poznan, Poland
Aclaris Investigational Site
Poznan, Poland
Aclaris Investigational Site
Sochaczew, Poland
Aclaris Investigational Site
Torun, Poland
Aclaris Investigational Site
Warsaw, Poland
Aclaris Investigational Site
Wroclaw, Poland
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.